Loblaw, a major grocery retailer, reported increased profits in the second quarter driven by strong performance in its discount chains No Frills and Maxi. The company highlighted significant growth in its pharmacy unit, attributing it to the popularity of generic GLP-1 weight loss medications.
The financial results for the three-month period ending June 20 revealed that Loblaw’s revenue exceeded $15.3 billion, marking a four percent increase from the previous quarter. The company’s profit available to common shareholders rose by five percent to $751 million.
Loblaw noted a 1.6 percent rise in same-store sales for its core retail food business, while its drug retail unit, which includes Shoppers Drug Mart, experienced a 4.6 percent increase in same-store sales, primarily fueled by a 7.5 percent growth in pharmacy and health-care services.
During a conference call with analysts, Richard Dufresne, the chief financial officer, highlighted the positive impact of generic GLP-1 drugs on the company’s pharmacy performance. He mentioned that despite lower generic drug prices, higher volumes are driving increased revenue, gross profit dollars, and gross margin rates.
The company’s executives reported a 40 percent year-to-date increase in GLP-1 drug sales, a trend observed since the prior quarter. Loblaw’s CEO, Per Bank, mentioned that consumers are opting for frozen vegetables over fresh produce due to inflation, with a notable rise in frozen veg sales at No Frills and Maxi stores.
Despite food price inflation, Loblaw’s No Frills and Maxi stores are attracting value-conscious customers, positioning the company well in the market. The company continues to excel in the hard discount sector, outperforming competitors in conventional retail.
Inflation in Canada eased to 2.8 percent in June, with grocery price increases moderating to 3.9 percent from 4.3 percent in May, according to Statistics Canada. Loblaw’s stock, listed in Toronto, traded relatively unchanged on Thursday and has shown a six percent increase year-to-date.